Home › Major Depressive Disorder › New York
Major Depressive Disorder clinical trials in New York
42 studies for Major Depressive Disorder are looking for participants at sites in New York.
Cities in New York
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Adams Clinical Harlem, New York
- New York State Psychiatric Institute, New York
- Adams Clinical Bronx, The Bronx
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Nov 13, 2026 · NCT06793397The Role of mGluR5 in CBT-I
- Stony Brook University: Dept of Psychiatry, Stony Brook
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07076342A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Brooklyn
- Seaport Investigator Site, Cedarhurst
- Seaport Investigator Site, New York
- and 1 more
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 10, 2026 · NCT07065240Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York
RecruitingPhase 2
Ages 21 to 80 · All sexes · Updated Nov 6, 2026 · NCT06592833ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Integrative Clinical Trials LLC, Brooklyn
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 5, 2026 · NCT07284667Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Nov 4, 2026 · NCT06559826A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Adams Clinical Harlem, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 4, 2026 · NCT07412756Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Integrative Clinical Trials LLC, Brooklyn
- SPRI Clinical Trials, LLC, Brooklyn
- Bioscience Research LLC, Mount Kisco
- and 1 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT06559306A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Adams Clinical Bronx, The Bronx
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 3, 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- SPRI Clinical Trials, LLC, Brooklyn
- Manhattan Behavioral Medicine, New York
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Nov 3, 2026 · NCT05850689A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Bioscience Research LLC, Mount Kisco
- Fieve Clinical Research Inc, New York
- Adams Clinical Harlem, New York
- and 1 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, Mount Kisco
- Neurocrine Clinical Site, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06966401Dupilumab in Major Depressive Disorder
- The Dennis S. Charney, MD, Depression and Anxiety Discovery Center, New York
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Nov 2, 2026 · NCT07908563A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Clinical Research Site, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07621237Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- SPRI Clinical Trials, Brooklyn
- Manhattan Behavioral Medicine, New York
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 28, 2026 · NCT07226661Study of ALTO-300 in MDD
- Site 283, New York
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT05922878A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Glen Oaks
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07196501Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Mount Sinai Hospital, New York
Recruiting
Ages 22 to 70 · All sexes · Updated Oct 16, 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, New York
- Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 14, 2026 · NCT07610473Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Brooklyn
- Clinical Research Site, New York
- Clinical Research Site, New York
- and 2 more
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Oct 13, 2026 · NCT07484217A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 8, 2026 · NCT07300969Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, New York
- Vanda Investigational Site, New York
- Vanda Investigational Site, Staten Island
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044DBS for TRD With the Medtronic Percept PC
- Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York
Recruiting
Ages 25 to 70 · All sexes · Updated Sep 22, 2026 · NCT05773755Pattern Separation in Major Depressive Disorder
- New York State Psychiatric Institute (NYSPI), New York
RecruitingPhase 1
Ages 18 to 50 · All sexes · Updated Sep 15, 2026 · NCT07139834NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06963021Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Neurobehavioral Research, Inc., Cedarhurst
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Neurobehavioral Research, Inc, Cedarhurst
- IMA Clinical Research - NYC Midtown, New York
- IMA Clinical Research - NYC Uptown, New York
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Ima Clinical Research - Manhattan /ID# 278212, New York
- Manhattan Behavioral Medicine /ID# 277910, New York
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997tDCS: Sleep to Mood in Depression (S2M-D)
- NYU Langone Health, New York
Recruiting
Ages 18 to 65 · All sexes · Updated Jun 8, 2026 · NCT07572526Triage Survey for Psychiatry Research Eligibility
- Adams Clinical, Harlem, New York
- Adams Clinical, Bronx, The Bronx
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05800925Aβ Dynamics in LLMD
- NYU Langone Health, New York
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg
RecruitingPhase 4
Ages 60 and older · All sexes · Updated May 6, 2026 · NCT05004987Mindfulness-Based fMRI Neurofeedback for Depression
- Columbia University Irving Medical Center, New York
Recruiting
Ages 13 to 18 · All sexes · Updated Apr 29, 2026 · NCT05617495Maintenance rTMS for Depression (Maitr-De)
- Weill Cornell Medicine, New York
Recruiting
Ages 18 to 80 · All sexes · Updated Apr 29, 2026 · NCT06938841Neutralizing Interleukin (IL)-6
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Apr 29, 2026 · NCT07493317Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
- Weill Cornell Medicine, New York
Recruiting
Ages 50 to 80 · All sexes · Updated Mar 27, 2026 · NCT05925322Biomarker-guided rTMS for Treatment Resistant Depression
- Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 22 to 65 · All sexes · Updated Feb 25, 2026 · NCT04041479Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
- NYU Langone Health, New York
- Nathan Kline Institute for Psychiatric Research, Orangeburg
Recruiting
Ages 18 to 65 · All sexes · Updated Feb 5, 2026 · NCT05573074Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #105, Brooklyn
- Autobahn Site #134, Brooklyn
- Autobahn Site #104, Staten Island
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mount Kisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.